These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20702966)

  • 21. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
    J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
    Aspromonte N; Colivicchi F
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban.
    Masjuan J; DeFelipe A
    Int J Neurosci; 2017 Aug; 127(8):716-725. PubMed ID: 27586690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban: a focused review of its clinical pharmacology.
    Lip GY; Agnelli G
    Eur Heart J; 2014 Jul; 35(28):1844-55. PubMed ID: 24810388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial.
    Veltkamp R; Prabhakaran S
    Stroke; 2014 Jul; 45(7):2151-3. PubMed ID: 24916907
    [No Abstract]   [Full Text] [Related]  

  • 27. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
    Xiong Q; Lau YC; Lip GY
    J Comp Eff Res; 2015 Aug; 4(4):367-76. PubMed ID: 26274798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux.
    Wolzt M; Samama MM; Kapiotis S; Ogata K; Mendell J; Kunitada S
    Thromb Haemost; 2011 Jun; 105(6):1080-90. PubMed ID: 21544313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing.
    Partida RA; Giugliano RP
    Future Cardiol; 2011 Jul; 7(4):459-70. PubMed ID: 21797743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Edoxaban (Savaysa) for the Prevention of Thromboembolic Events.
    Oung AB
    Am Fam Physician; 2018 Apr; 97(8):529-530. PubMed ID: 29671492
    [No Abstract]   [Full Text] [Related]  

  • 31. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
    Barrios V; Escobar C
    Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E; Galán AM
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):445-58. PubMed ID: 24471416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
    Brekelmans M; Middeldorp S; Coppens M
    Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban, a Novel Oral Factor Xa Inhibitor.
    Minor C; Tellor KB; Armbruster AL
    Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
    Morishima Y; Honda Y; Kamisato C; Shibano T
    Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
    Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
    Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A
    Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.
    Salazar DE; Mendell J; Kastrissios H; Green M; Carrothers TJ; Song S; Patel I; Bocanegra TS; Antman EM; Giugliano RP; Kunitada S; Dornseif B; Shi M; Tachibana M; Zhou S; Rohatagi S
    Thromb Haemost; 2012 May; 107(5):925-36. PubMed ID: 22398655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.